Immunoglobulin single variable domain antibody against RSV prefusion F protein
AssigneesV18 Vzw, Universiteit Gent, The United States of America as represented by the Secretary of Health and Human Services, Trustees of Dartmouth College
InventorsXavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.
Claims12
An immunoglobulin single variable domain (ISVD) that binds specifically to the prefusion form of the fusion (F) protein of respiratory syncytial virus (RSV), characterized in that the ISVD shows in monovalent format a neutralization activity of RSV serotypes A and B for which the IC50 value differs ten-fold or less, and in that the ISVD binds to a conformational epitope of RSV prefusion F protein comprising amino acids 50-52, 180, 184, 185, 265-270, 305, 307, 308, 345-347, 421, 425, 427-431, 451, 453, 454, 456 and 458 as depicted in SEQ ID NO:
- 17, characterized in that said ISVD comprises CDR1 sequence SEQ ID NO:
- 1, a CDR2 sequence selected from the group consisting of SEQ ID NO:
- 3 and SEQ ID NO:
- 4, and a CDR3 sequence selected from the group consisting of SEQ ID NO:
- 5 and SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.